Useful objective analysis. I own both ZSPH and RLYP, but am relatively overweight RLYP. I am thinking of readjusting the balance here.
Frankly, I didn't even know that Menieres trial data was in the offing. I wouldn't look for it to go up to 28 real soon. I added a few more shares today at 23.58. I wouldn't be surprised to see it drop back down to that level again, and if it does I'll add some more.
Well, I would stick my toe in cautiously for some additional shares here. But I wouldn't double down just yet.
Terrible news. At this rate, they may not be able to pay off all their debt in 2015. Although, on the plus side, the recent weakness has lowered the p/e to a fairly reasonable 4.3.
Excellent analysis. Instead of anticipating a quick double on a buyout - which I don't think was realistic, given the multitude of HepC players - we now have the prospect of a longer term play. Fine by me.
Well, look at it as a secondary priced at 12.25. It may not get all the way up there right away, but it should move closer to 12 than 10, I believe.
Once again, in the interests of accuracy, I have to point out that Rep.Waxman was largely responsible for the Orphan Drug Act and the Ryan White CARE Act which mandated treatment for HIV. Without the latter, Gilead could not have prospered as it has. He was also instrumental in the expansion of Medicare and Medicaid, which has helped enrich the healthcare industry. The fact that he is retiring and is now positioning himself as a advocate of affordable healthcare - no doubt anticipating some nice lobbying assignments for HMO's - should not diminish the fact that he helped make it unaffordable.
JNJ is buying 18 million shares @ $12.25. It seems to me like the opportunity to buy shares from disappointed longs at 10 - 10.40 is attractive. I think this may open closer to JNJ's price tomorrow.
I think the selling here is on the part of the retail speculators who had their heart set on a $20 buyout. Nevertheless, this deal adds value to the company, I think. Let's see where it opens in the morning.
Just to point out that both sovraprevir and ACN-3102 have already been granted Fast Track status by the FDA.
The dollar spiked against other currencies today, which suggests that travel to the US by foreigners will drop off. Of course, an American booking a roundtrip to Europe may well replace a European coming to Disneyland. The Latin American traffic is another issue.
The possibility of an acquisition by JNJ or MDVN might also be considered. This company is not expensive.
I suspect that you are buying June calls for a short term profit (which may not be a bad idea). I am buying the stock to hold as a long term investment.